Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pcgin** is an engineered derivative of progranulin (PGRN) bearing the granulin E domain, developed as a chemically stable therapeutic agent for lysosomal storage disorders. It functions as a chaperone that binds to lysosomal enzymes such as beta-glucocerebrosidase (GBA) and hexosaminidase A (HexA), recruiting heat shock protein 70 (HSP70) to enhance their enzymatic activity, lysosomal delivery, and reduce substrate accumulation like glucocerebroside in Gaucher disease (GD) and GM2 ganglioside in Tay-Sachs disease (TSD). Studies in patient fibroblasts and progranulin-deficient mouse models demonstrate Pcgin reduces GBA clumping by up to 40%, GM2 storage, and associated pathologies; it also shows preliminary efficacy in reducing lung swelling in asthma models and potential blood-brain barrier penetration for neuropathic GD.[3][4][5][7][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pcgin.